A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Introduction: Chimeric antigen receptor (CAR)-T cell therapy is limited in most cases to inpatient use due to risk of severe treatment-related toxicities. The two primary toxicities observed with CAR-T therapy, cytokine release syndrome (CRS) and neurotoxicity, are associated with increased circulat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.2814-2814
Hauptverfasser:	Frigault, Matthew J., Gallagher, Kathleen M.E., Wehrli, Marc, Valles, Betsy, Casey, Keagan, Lindell, Kevin, Trailor, Michael, Cho, Hana, Brown, Jami L., Horick, Nora K., Chou, Justin, Shen, Rhine R., Filosto, Simone, Bot, Adrian, Maus, Marcela V.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!